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searchers, Jian Wang and Huanming
Yang, founded Beijing Genomics Institute
in Beijing, China, as a genomics
sequencing center. Its mission and suc-
cess have increased exponentially and
extend beyond simple sequencing to
developing new genomics and nonge-
nomics technologies and applying them
to research and clinical applications.
Within the past 2 years, the company,
now known as BGI, has expanded glob-
ally, establishing satellite laboratories in
the United States and Europe.
Based in Cambridge, Massachusetts,
BGI Americas was established in April
2010 as a revenue-producing commercial
sequencing arm. With customers locatedBGI is undeniably the largest genomics-based research organiza-
tion in the world.in North, South, and Central America—
including some pharmaceutical com-
panies and other commercial com-
panies—BGI Americas is part of BGI’s
global commercial arm that was estab-
lished to provide commercial sequencing
services and to facilitate research collabo-
rations between scientists at universities,
healthcare facilities,andwithin the industry
with the company’s massive China-based
research engine. BGI Europe serves a
similar function in its geographic area.
In the 14 years that BGI has been in
operation, it has developed a commercial
funding network of organizations to pro-
vide the capital needed to support
more than 4,000 BGI employees, most
of them based in China. The parent orga-
nization remains a not-for-profit institute,
although it receives some Chinese gov-
ernment funding. Increasingly, its needed
capital now derives from for-profit, fee-
for-service umbrella organizations like
BGI Americas and BGI Europe.
‘‘BGI Americas is still evolving but
was first established as a gateway for sci-entific collaborations and for providing
sequencing services to clients and re-
searchers in the Americas,’’ explains
Joyce Peng, Marketing Director, BGI
Americas, of the parent company’s desire
to provide a more comprehensive, con-
venient way for researchers in the region
to collaborate and tap into BGI’s next-
generation sequencing expertise. Most
of the 40 employees within BGI Americas
focus on commercial sequencing sales,
fostering scientific collaborations, and
project management.
Expansive Scientific Collaborations
To provide local sequencing services in
the United States and expand its global
research presence, BGI Americas haspartnered with two US-based labora-
tories offering next-generation sequenc-
ing: one at the Children’s Hospital
Philadelphia (CHOP) and the other at
the University of California, Davis. Both
of these laboratories work on sequencing
samples for their own projects as well
as those from external researchers. Both
partnerships are also designed to expe-
dite research collaborations.
The BGI/CHOP partnership, known as
the BGI@CHOP next-generation core,
focuses on the discovery of genes related
to pediatric diseases. While CHOP had
already established a next-generation
sequencing research capability within its
own pathology department, the relation-
ship with BGI is seen as a means of accel-
erating CHOP’s deployment of next
generation sequencing in research and
ultimately in the clinic.
The collaboration is an extension of
an established academic relationship
between investigators at CHOP’s Center
for Applied Genomics and BGI. ‘‘What
really interested us in working moreChemistry & Biology 20, June 20, 2013expansively with BGI was their wealth of
experience and depth of talent in infor-
matics,’’ explains Thomas Curran, Ph.D.,
Deputy Scientific Director, CHOP
Research Institute. ‘‘To apply next-gener-
ation sequencing optimally, one needs
to think closely about the kind of data to
be generated and particularly how to
interrogate that data to understand
biology.’’ He views the relationship as
a broad-ranging collaboration pairing
CHOP investigators with BGI infor-
matics expertise to best design projects,
mine the data, and achieve scientific
breakthroughs.
As one of its first research endeavors,
BGI and CHOP jointly initiated the 1,000
Rare Diseases Project, whose mission is
to use next-generation sequencing of
clinical isolates to expedite discovery of
genetic variants associated with 1,000
rare diseases. Presently, the BGI/CHOP
team is working on rare pediatric cancers
but ultimately look to expand next-gener-
ation sequencing across a much wider
range of illnesses and all areas of
pediatric medicine.
CHOP is in the final stages of com-
pleting a CLIA CAP-certified facility that
will support research projects but will
ultimately perform as a next-generation
clinical diagnostic facility.
At BGI@UCDavis, scientists are
focused on the genomic study of agricul-
tural disease as well as human, animal,
and environmental health and microbial
science. Similar to CHOP, UC Davis
had been pursuing next-generation
sequencing; in their case, particularly for
environmental microbial biology projects.
UC Davis chose to partner with BGI to
build a production-scale sequencing
facility large enough and with enough
expertise to provide services not only
to UC Davis researchers but to any
customer looking for fee-for-service
sequencing or to partner with their
researchers on large-scale projects.
‘‘We chose BGI for our strategic
partnership because it enables ourª2013 Elsevier Ltd All rights reserved 743
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to come to our campus and work with
an organization that has world-wide
reach and many capabilities besides
sequencing,’’ explains Bart Weimer,
PhD, Codirector, BGI@UCDavis. Like
CHOP’s Curran, Weimer cites BGI’s infor-
matics abilities as a strong draw; also
similar to CHOP, UCDavis has an estab-
lished Genome Center already working
on genome sequencing. ‘‘But when you
have a partner that has scale across the
world from the United States, Europe to
Asia, even Australia, then it becomes
very compelling from our perspective
to start partnering with that sort of organi-
zation,’’ he adds.
BGI@UCDavis is a key player in the
ongoing 100K Pathogenic Genome
Project, a project funded by the FDA
and Agilent Technologies to sequence
100,000 of the most common foodborne,
disease-causing pathogenic bacteria.
The aim of the project is to improve food
safety and reduce foodborne illness,
including outbreaks from Salmonella,
Campylobacter, enteropathogenic E. coli,
Listeria monocytogenes, Vibrio, and
Shigella. In May 2013, the project
announced the genomes of its first ten
infectious microorganisms, including
strains of Salmonella and Listeria. Many
of the project’s microbial isolates are
sourced beyond US borders, and Weimer
is enthusiastic that the partnership can
draw on the sequencing capabilities of
other BGI sequencing sites globally to
better service the project.
Beyond the 100K Genome Project, the
partnership is gearing up for projects744 Chemistry & Biology 20, June 20, 2013 ªin sequencing commodity crops like
maize, pine tree sequencing, and some
cancer microbiome components. The
BGI@UCDavis facility is expected to be
complete in September 2013.
Educational Outreach
Beyond its research collaborations, BGI
Americas has entered the conferences
arena to share the latest in genomics
research. In September 2013, BGI Ameri-
cas will be sponsoring the International
Conference on Genomics (ICG) in the
Americas, now in its second year, along
with its UC Davis partners. Last year’s
meeting was cosponsored by CHOP.
ICG Americas is modeled after BGI’s
International Conferences on Genomics
held in China annually since 2006.
Speakers at ICG Americas also include
those from biotechnology and the
pharmaceutical industry, highlighting the
expanding reach BGI Americas also has
into for-profit business.
In China, BGI’s educational efforts also
include funding degrees with universities
in China for Ph.D.-level students seeking
a career in genomics research.
The Global Parent
BGI is undeniably the largest genomics-
based research organization in the world.
Its goal—to continue to sequence more
species and develop applications for
agriculture and medicine—continues to
thrive thanks to its global presence and
large numbers of experienced genomics
researchers and informaticians. To date,
its researchers have published over
250 papers in leading journals, many of2013 Elsevier Ltd All rights reservedthem dedicated to sequencing more
than 600 different animal and plant
species for the first time, including its
famous 2009 publication of the Chinese
panda bear genome sequence and de
novo assembly. Its labs house more than
160 sequencers.
‘‘BGI has enormous capacity and is
giving access to it, either through financial
incentives or scientific interactions,’’ says
Edward Rubin, M.D., Ph.D., Director, DOE
Joint Genome Institute (JGI). JGI was
one of five centers from the public sector,
also including Baylor University, Wash-
ington University, MIT, and the Sanger
Institute, that contributed to sequencing
the human genome for the first time.
They contributed approximately 12%–
13% of the human genome sequence
and have since shifted sequencing
studies to organisms of relevance to
energy and the environment.
As a result of its expansive capacity,
BGI’s efforts extend into almost any area
involving genomics research including
human and animal disease and plant and
microbial genomics. It also is a major
developer of new technologies and big
data analysis tools designed to make
sense of all of the data flowing from its
sequencers. Going forward, the company
will be focusing more on the health indus-
try by developing clinical diagnostics
based on genomics. Says Peng, ‘‘That is
an area where we hope tomake an impact
on diseases globally by providing more
diagnostic depth on a global basis.’’AliceMcCarthy (alice@alicemccarthy.com) is a sci-
ence writer based in Gloucester, Massachusetts.
